Prospects and challenges of CAR-T cell therapy combined with ICIs

被引：23

作者：

Lv, Yufan ^{[1
]}

Luo, Xinyu ^{[1
]}

Xie, Zhuoyi ^{[2
]}

Qiu, Jieya ^{[2
]}

Yang, Jinsai ^{[3
]}

Deng, Yuqi ^{[2
]}

Long, Rou ^{[2
]}

Tang, Guiyang ^{[2
]}

Zhang, Chaohui ^{[1
]}

Zuo, Jianhong ^{[1
,2
,3
,4
]}

机构：

[1] Univ South China, Affiliated Nanhua Hosp, Hengyang Med Sch, Hengyang, Peoples R China

[2] Univ South China, Hengyang Med Sch, Transformat Res Lab, Hengyang, Hunan, Peoples R China

[3] Univ South China, Comp Inst, Hengyang Med Sch, Hengyang, Hunan, Peoples R China

[4] Univ South China, Affiliated Hosp 3, Hengyang Med Sch, Hengyang, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2024年 / 14卷

关键词：

immunotherapy; immune checkpoints; CAR-T cells; combination therapy; solid tumors; MULTIPLE-MYELOMA; PD-1; IMMUNOTHERAPY; COMBINATION; ANTI-CTLA-4; HYALURONAN; EXHAUSTION; EFFICACY; TUMORS;

D O I：

10.3389/fonc.2024.1368732

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint molecules are a group of molecules expressed on the surface of immune cells that primarily regulate their immune homeostasis. Chimeric antigen receptor (CAR) T cell therapy is an immunotherapeutic technology that realizes tumor-targeted killing by constructing synthetic T cells expressing specific antigens through biotechnology. Currently, CAR-T cell therapy has achieved good efficacy in non-solid tumors, but its treatment of solid tumors has not yielded the desired results. Immune checkpoint inhibitors (ICIs) combined with CAR-T cell therapy is a novel combination therapy with high expectations to defeat solid tumors. This review addresses the challenges and expectations of this combination therapy in the treatment of solid tumors.

引用

页数：12

共 126 条

[1] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].

Abramson, Jeremy S. ;

Palomba, M. Lia ;

Gordon, Leo I. ;

Lunning, Matthew A. ;

Wang, Michael ;

Arnason, Jon ;

Mehta, Amitkumar ;

Purev, Enkhtsetseg ;

Maloney, David G. ;

Andreadis, Charalambos ;

Sehgal, Alison ;

Solomon, Scott R. ;

Ghosh, Nilanjan ;

Albertson, Tina M. ;

Garcia, Jacob ;

Kostic, Ana ;

Mallaney, Mary ;

Ogasawara, Ken ;

Newhall, Kathryn ;

Kim, Yeonhee ;

Li, Daniel ;

Siddiqi, Tanya .

LANCET, 2020, 396 (10254) :839-852

[2] A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab [J].

Adusumilli, Prasad S. ;

Zauderer, Marjorie G. ;

Riviere, Isabelle ;

Solomon, Stephen B. ;

Rusch, Valerie W. ;

O'Cearbhaill, Roisin E. ;

Zhu, Amy ;

Cheema, Waseem ;

Chintala, Navin K. ;

Halton, Elizabeth ;

Pineda, John ;

Perez-Johnston, Rocio ;

Tan, Kay See ;

Daly, Bobby ;

Araujo Filho, Jose A. ;

Ngai, Daniel ;

McGee, Erin ;

Vincent, Alain ;

Diamonte, Claudia ;

Sauter, Jennifer L. ;

Modi, Shanu ;

Sikder, Devanjan ;

Senechal, Brigitte ;

Wang, Xiuyan ;

Travis, William D. ;

Gonen, Mithat ;

Rudin, Charles M. ;

Brentjens, Renier J. ;

Jones, David R. ;

Sadelain, Michel .

CANCER DISCOVERY, 2021, 11 (11) :2748-2763

[3] Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells [J].

Agarwal, Sangya ;

Aznar, M. Angela ;

Rech, Andrew J. ;

Good, Charly R. ;

Kuramitsu, Shunichiro ;

Da, Tong ;

Gohil, Mercy ;

Chen, Linhui ;

Hong, Seok-Jae Albert ;

Ravikumar, Pranali ;

Rennels, Austin K. ;

Salas-Mckee, January ;

Kong, Weimin ;

Ruella, Marco ;

Davis, Megan M. ;

Plesa, Gabriela ;

Fraietta, Joseph A. ;

Porter, David L. ;

Young, Regina M. ;

June, Carl H. .

IMMUNITY, 2023, 56 (10) :2388-2407.e9

[4] αPD- 1- mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib(vol 9, e001162, 2021) [J].

Fang, J. ;

Ding, N. ;

Guo, X. .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (01)

[5] Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer [J].

Ao, Xiang ;

Yang, Yu ;

Li, Weiqiang ;

Tan, Yan ;

Guo, Wei ;

Ao, Luoquan ;

He, Xiao ;

Wu, Xiaofeng ;

Xia, Jianchuan ;

Xu, Xiang ;

Guo, Jianxin .

JOURNAL OF IMMUNOTHERAPY, 2019, 42 (08) :284-296

[6] Endogenous Nur77 Is a Specific Indicator of Antigen Receptor Signaling in Human T and B Cells [J].

Ashouri, Judith F. ;

Weiss, Arthur .

JOURNAL OF IMMUNOLOGY, 2017, 198 (02) :657-668

[7] Molecular Basis of DNA Recognition in the Immune System [J].

Atianand, Maninjay K. ;

Fitzgerald, Katherine A. .

JOURNAL OF IMMUNOLOGY, 2013, 190 (05) :1911-1918

[8] Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study [J].

Berdeja, Jesus G. ;

Madduri, Deepu ;

Usmani, Saad Z. ;

Jakubowiak, Andrzej ;

Agha, Mounzer ;

Cohen, Adam D. ;

Stewart, A. Keith ;

Hari, Parameswaran ;

Htut, Myo ;

Lesokhin, Alexander ;

Deol, Abhinav ;

Munshi, Nikhil C. ;

O'Donnell, Elizabeth ;

Avigan, David ;

Singh, Indrajeet ;

Zudaire, Enrique ;

Yeh, Tzu-Min ;

Allred, Alicia J. ;

Olyslager, Yunsi ;

Banerjee, Arnob ;

Jackson, Carolyn C. ;

Goldberg, Jenna D. ;

Schecter, Jordan M. ;

Deraedt, William ;

Zhuang, Sen Hong ;

Infante, Jeffrey ;

Geng, Dong ;

Wu, Xiaoling ;

Carrasco-Alfonso, Marlene J. ;

Akram, Muhammad ;

Hossain, Farah ;

Rizvi, Syed ;

Fan, Frank ;

Lin, Yi ;

Martin, Thomas ;

Jagannath, Sundar .

LANCET, 2021, 398 (10297) :314-324

[9] Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma [J].

Bjoern, Jon ;

Lyngaa, Rikke ;

Andersen, Rikke ;

Rosenkrantz, Lisbet Holmich ;

Hadrup, Sine Reker ;

Donia, Marco ;

Svane, Inge Marie .

ONCOTARGET, 2017, 8 (16) :27062-27074

[10] Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination [J].

Boutros, Celine ;

Tarhini, Ahmad ;

Routier, Emilie ;

Lambotte, Olivier ;

Ladurie, Francois Leroy ;

Carbonnel, Franck ;

Izzeddine, Hassane ;

Marabelle, Aurelien ;

Champiat, Stephane ;

Berdelou, Armandine ;

Lanoy, Emilie ;

Texier, Matthieu ;

Libenciuc, Cristina ;

Eggermont, Alexander M. M. ;

Soria, Jean-Charles ;

Mateus, Christine ;

Robert, Caroline .

NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (08) :473-486

← 1 2 3 4 5 6 7 8 9 10 →